NASDAQ$KALA
Kala Bio Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Kala Pharmaceuticals' financial results for Q3 2021 were reported, showing a net product revenue of $3.1 million and a 19% increase in EYSUVIS prescriptions compared to the previous quarter.
Kala Pharmaceuticals reported a net product revenue of $3.1 million for the third quarter of 2021. EYSUVIS prescriptions increased by 19% compared to the second quarter of 2021. The company also acquired Combangio, expanding its clinical-stage pipeline.
- Net product revenues reached $3.1 million, with $1.83 million from EYSUVIS and $1.24 million from INVELTYS.
- EYSUVIS prescriptions increased by 19% compared to the prior quarter.
- Kala acquired Combangio, expanding its pipeline with KPI-012 for ocular surface diseases.
- Cash and cash equivalents totaled $124.5 million as of September 30, 2021.
Headline financials
Revenue & EPS history
Kala Bio · Revenue · Quarterly
$3.07M
Forward guidance
Kala anticipates that its cash resources as of September 30, 2021, together with anticipated revenue from EYSUVIS and INVELTYS and certain cost containment measures, will enable it to fund its operations until the second quarter of 2023.
Tailwinds
- Continued growth in EYSUVIS prescriptions.
- Expansion of formulary coverage for EYSUVIS.
- Advancement of pipeline programs, including rTKI and SEGRM.
- Planned submission of IND application for KPI-012.
- Potential initiation of Phase 2/3 trial for PCED in Q3 2022.
Headwinds
- Continued weakness in the ocular surgery market from COVID-19.
- Removal of INVELTYS from the CVS/Caremark formulary coverage list.
- Uncertainty around the impact and duration of the COVID-19 pandemic on elective procedures, which includes ocular surgeries.
- Operating loss of $26.1 million for the quarter ended September 30, 2021.
- Net loss of $28.1 million for the quarter ended September 30, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+1.5%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-4.7%
Avg return
30 days after
40%
14 / 35 earnings
Positive
+119.7%
Q4 2022
Best reaction
-18.3%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.6% | -17.4% | -17.7% | |
| Q3 2025 | -7.4% | -10.4% | -9.7% | |
| Q2 2025 | +2.0% | +9.9% | +103.2% | |
| Q1 2025 | -5.0% | +4.6% | +23.6% | |
| Q4 2024 | -1.5% | +1.5% | +0.0% | |
| Q3 2024 | -6.1% | -9.5% | -17.7% | |
| Q2 2024 | +3.2% | -1.7% | -1.7% | |
| Q1 2024 | -0.9% | -3.9% | -12.0% | |
| Q4 2023 | +0.3% | -2.4% | -21.0% | |
| Q3 2023 | -6.6% | -2.2% | +19.7% | |
| Q2 2023 | -6.5% | -8.4% | -7.9% | |
| Q1 2023 | -2.8% | +3.0% | -5.3% | |
| Q4 2022 | +119.7% | +114.5% | +48.0% | |
| Q3 2022 | +23.7% | +34.9% | -1.9% | |
| Q2 2022 | -3.4% | -4.6% | -1.7% | |
| Q1 2022 | +8.2% | -5.4% | -43.1% | |
| Q4 2021 | -16.6% | -25.1% | -61.9% | |
| Q3 2021 | +4.3% | -7.7% | -30.4% | |
| Q2 2021 | -6.3% | -4.8% | -2.7% | |
| Q1 2021 | -18.3% | -18.4% | -9.0% | |
| Q4 2020 | -17.0% | -17.6% | -21.4% | |
| Q3 2020 | -1.8% | +0.6% | +2.5% | |
| Q2 2020 | -2.7% | -2.5% | -13.2% | |
| Q1 2020 | -2.8% | +2.8% | +17.0% | |
| Q4 2019 | +3.5% | +1.6% | +1.3% | |
| Q3 2019 | +7.0% | -4.4% | +4.2% | |
| Q2 2019 | +1.2% | -0.6% | -20.6% | |
| Q1 2019 | -8.6% | -17.2% | -24.2% | |
| Q4 2018 | +1.0% | +6.6% | -1.6% | |
| Q3 2018 | -5.4% | -13.8% | -25.9% | |
| Q2 2018 | +1.6% | -3.9% | -8.5% | |
| Q1 2018 | +2.0% | +3.7% | -16.0% | |
| Q4 2017 | -7.1% | -7.4% | -7.4% | |
| Q3 2017 | -3.6% | +2.6% | +1.7% | |
| Q2 2017 | +5.4% | +6.2% | -3.7% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro